You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Pazopanib hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for pazopanib hydrochloride and what is the scope of patent protection?

Pazopanib hydrochloride is the generic ingredient in two branded drugs marketed by Apotex, Sun Pharm, Teva Pharms Inc, and Novartis, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for pazopanib hydrochloride. Five suppliers are listed for this compound.

Summary for pazopanib hydrochloride
Recent Clinical Trials for pazopanib hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alliance for Clinical Trials in OncologyPhase 2/Phase 3
Shenzhen Chipscreen Biosciences Co.LtdPhase 2
Fondation ARCPhase 1/Phase 2

See all pazopanib hydrochloride clinical trials

US Patents and Regulatory Information for pazopanib hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 215837-001 Oct 19, 2023 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Apotex PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 217713-001 Oct 19, 2023 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Teva Pharms Inc PAZOPANIB HYDROCHLORIDE pazopanib hydrochloride TABLET;ORAL 217517-001 Oct 19, 2023 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for pazopanib hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.